Summarized from multiple reports,
Pfizer and
BioNTech halted their COVID-19
vaccine study in the US because of low enrollment. BioNTech is facing several key changes: the co-founders are planning to step away to form a new
mRNA-focused company; the
Singapore plant will close by 2027; and a pivot towards
oncology with a goal for multiproduct oncology status by 2030 is underway. An earning call noted a
cash-rich pivot beyond COVID. A
lawsuit for patent infringement against
Moderna was filed by BioNTech. A negative estimate has been issued by
HC Wainwright; their stock has also witnessed a
downfall. The company’s
annual general meeting was announced for 2026. A Belgian court ordered Poland and Romania to buy Pfizer COVID shots worth $2.2 billion. Finally, BioNTech is advancing a precision drug with DualityBio into a phase 3 trial. Plans are revealed for an mRNA vaccine production in
Rwanda, priming for a pivot into oncology.
BIONTECH News Analytics from Thu, 10 Jul 2025 07:00:00 GMT to Sun, 05 Apr 2026 01:54:59 GMT -
Rating -6
- Innovation 3
- Information 6
- Rumor -6
